Mckinley Capital Management LLC Delaware Boosts Stake in Stryker Co. (NYSE:SYK)

Mckinley Capital Management LLC Delaware boosted its stake in shares of Stryker Co. (NYSE:SYK) by 19.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 147,734 shares of the medical technology company’s stock after buying an additional 24,108 shares during the period. Stryker accounts for about 1.9% of Mckinley Capital Management LLC Delaware’s investment portfolio, making the stock its 14th biggest holding. Mckinley Capital Management LLC Delaware’s holdings in Stryker were worth $30,371,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Founders Capital Management LLC lifted its holdings in Stryker by 3.9% during the second quarter. Founders Capital Management LLC now owns 10,887 shares of the medical technology company’s stock worth $2,238,000 after buying an additional 411 shares during the period. Clarus Wealth Advisors increased its position in shares of Stryker by 19.3% during the second quarter. Clarus Wealth Advisors now owns 2,111 shares of the medical technology company’s stock worth $434,000 after purchasing an additional 342 shares in the last quarter. Bbva Compass Bancshares Inc. increased its position in shares of Stryker by 1.1% during the first quarter. Bbva Compass Bancshares Inc. now owns 11,663 shares of the medical technology company’s stock worth $2,304,000 after purchasing an additional 123 shares in the last quarter. MainStreet Investment Advisors LLC increased its position in shares of Stryker by 3.9% during the first quarter. MainStreet Investment Advisors LLC now owns 15,532 shares of the medical technology company’s stock worth $3,067,000 after purchasing an additional 589 shares in the last quarter. Finally, Advisory Services Network LLC increased its position in shares of Stryker by 2.9% during the first quarter. Advisory Services Network LLC now owns 15,004 shares of the medical technology company’s stock worth $2,963,000 after purchasing an additional 423 shares in the last quarter. Institutional investors own 74.14% of the company’s stock.

A number of equities analysts have recently issued reports on the company. Raymond James set a $240.00 price target on Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. Cantor Fitzgerald upped their price target on Stryker from $190.00 to $230.00 and gave the stock a “neutral” rating in a research report on Friday, July 26th. BTIG Research reaffirmed a “buy” rating and set a $228.00 price target on shares of Stryker in a research report on Monday, July 29th. Morgan Stanley upped their price target on Stryker from $218.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 16th. Finally, Wells Fargo & Co upped their price target on Stryker from $219.00 to $228.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 2nd. Five investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $214.89.

SYK traded down $4.17 during midday trading on Friday, hitting $214.10. 739,692 shares of the company were exchanged, compared to its average volume of 1,089,592. The company’s 50 day simple moving average is $212.38 and its 200 day simple moving average is $196.13. The firm has a market capitalization of $81.94 billion, a price-to-earnings ratio of 29.29, a price-to-earnings-growth ratio of 2.66 and a beta of 0.85. The company has a current ratio of 2.07, a quick ratio of 1.26 and a debt-to-equity ratio of 0.67. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $222.59.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.05. The company had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.60 billion. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $1.76 EPS. On average, equities analysts anticipate that Stryker Co. will post 8.21 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 0.97%. The ex-dividend date is Friday, September 27th. Stryker’s dividend payout ratio is currently 28.45%.

In other Stryker news, Director Allan C. Golston sold 3,399 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $209.84, for a total transaction of $713,246.16. Following the sale, the director now directly owns 13,762 shares of the company’s stock, valued at approximately $2,887,818.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $214.16, for a total value of $578,232.00. Following the sale, the chief financial officer now directly owns 20,633 shares in the company, valued at $4,418,763.28. The disclosure for this sale can be found here. Insiders have sold a total of 20,447 shares of company stock worth $4,262,634 over the last ninety days. 7.20% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Understanding Options Trading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.